Product Code: A00969
According to a new report published by Allied Market Research, titled, "Protein Engineering Market," The protein engineering market was valued at $2.2 billion in 2022, and is estimated to reach $7.7 billion by 2032, growing at a CAGR of 13.2% from 2023 to 2032.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
Key Market Segments
By End User
- Pharmaceutical and Biotechnology Companies
- Academic Research Institutes
- Contract Research Organizations
By Product
- Instruments
- Consumables
- Software
By Technology Type
- Rational or Site Directed Mutagenesis
- Irrational or Random Mutagenesis
By Protein Type
- Monoclonal Antibodies
- Insulin
- Erythropoietin
- Interferon
- Others
By Region
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- Agilent Technologies, Inc.
- Promega Corporation
- New England Biolabs, Inc.
- Danaher Corporation
- Bio-Rad Laboratories, Inc.
- Amgen, Inc.
- TAKARA HOLDINGS INC.
- Thermo Fisher Scientific Inc.
- Creative Biolabs Limited
- Jena Bioscience GmbH
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
- 3.1. Market definition and scope
- 3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
- 3.3.1. Moderate bargaining power of suppliers
- 3.3.2. Moderate threat of new entrants
- 3.3.3. Moderate threat of substitutes
- 3.3.4. High intensity of rivalry
- 3.3.5. Moderate bargaining power of buyers
- 3.4. Market dynamics
- 3.4.1. Drivers
- 3.4.1.1. Increasing research & development activities in the biopharmaceutical industry
- 3.4.1.2. Technological advancements in protein engineering
- 3.4.1.3. Increase in developmental strategies in protein engineering by key players
- 3.4.2. Restraints
- 3.4.2.1. High cost and maintenance of protein engineering systems
- 3.4.3. Opportunities
- 3.4.3.1. Growth in opportunities in emerging markets
CHAPTER 4: PROTEIN ENGINEERING MARKET, BY PRODUCT
- 4.1. Overview
- 4.1.1. Market size and forecast
- 4.2. Instruments
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.3. Consumables
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
- 4.4. Software
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country
CHAPTER 5: PROTEIN ENGINEERING MARKET, BY TECHNOLOGY TYPE
- 5.1. Overview
- 5.1.1. Market size and forecast
- 5.2. Rational or Site Directed Mutagenesis
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
- 5.3. Irrational or Random Mutagenesis
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
CHAPTER 6: PROTEIN ENGINEERING MARKET, BY PROTEIN TYPE
- 6.1. Overview
- 6.1.1. Market size and forecast
- 6.2. Monoclonal Antibodies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
- 6.3. Insulin
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
- 6.4. Erythropoietin
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country
- 6.5. Interferon
- 6.5.1. Key market trends, growth factors and opportunities
- 6.5.2. Market size and forecast, by region
- 6.5.3. Market share analysis by country
- 6.6. Others
- 6.6.1. Key market trends, growth factors and opportunities
- 6.6.2. Market size and forecast, by region
- 6.6.3. Market share analysis by country
CHAPTER 7: PROTEIN ENGINEERING MARKET, BY END USER
- 7.1. Overview
- 7.1.1. Market size and forecast
- 7.2. Pharmaceutical and Biotechnology Companies
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
- 7.3. Academic Research Institutes
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
- 7.4. Contract Research Organizations
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country
CHAPTER 8: PROTEIN ENGINEERING MARKET, BY REGION
- 8.1. Overview
- 8.1.1. Market size and forecast By Region
- 8.2. North America
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by Product
- 8.2.3. Market size and forecast, by Technology Type
- 8.2.4. Market size and forecast, by Protein Type
- 8.2.5. Market size and forecast, by End User
- 8.2.6. Market size and forecast, by country
- 8.2.6.1. U.S.
- 8.2.6.1.1. Market size and forecast, by Product
- 8.2.6.1.2. Market size and forecast, by Technology Type
- 8.2.6.1.3. Market size and forecast, by Protein Type
- 8.2.6.1.4. Market size and forecast, by End User
- 8.2.6.2. Canada
- 8.2.6.2.1. Market size and forecast, by Product
- 8.2.6.2.2. Market size and forecast, by Technology Type
- 8.2.6.2.3. Market size and forecast, by Protein Type
- 8.2.6.2.4. Market size and forecast, by End User
- 8.2.6.3. Mexico
- 8.2.6.3.1. Market size and forecast, by Product
- 8.2.6.3.2. Market size and forecast, by Technology Type
- 8.2.6.3.3. Market size and forecast, by Protein Type
- 8.2.6.3.4. Market size and forecast, by End User
- 8.3. Europe
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by Product
- 8.3.3. Market size and forecast, by Technology Type
- 8.3.4. Market size and forecast, by Protein Type
- 8.3.5. Market size and forecast, by End User
- 8.3.6. Market size and forecast, by country
- 8.3.6.1. Germany
- 8.3.6.1.1. Market size and forecast, by Product
- 8.3.6.1.2. Market size and forecast, by Technology Type
- 8.3.6.1.3. Market size and forecast, by Protein Type
- 8.3.6.1.4. Market size and forecast, by End User
- 8.3.6.2. France
- 8.3.6.2.1. Market size and forecast, by Product
- 8.3.6.2.2. Market size and forecast, by Technology Type
- 8.3.6.2.3. Market size and forecast, by Protein Type
- 8.3.6.2.4. Market size and forecast, by End User
- 8.3.6.3. UK
- 8.3.6.3.1. Market size and forecast, by Product
- 8.3.6.3.2. Market size and forecast, by Technology Type
- 8.3.6.3.3. Market size and forecast, by Protein Type
- 8.3.6.3.4. Market size and forecast, by End User
- 8.3.6.4. Italy
- 8.3.6.4.1. Market size and forecast, by Product
- 8.3.6.4.2. Market size and forecast, by Technology Type
- 8.3.6.4.3. Market size and forecast, by Protein Type
- 8.3.6.4.4. Market size and forecast, by End User
- 8.3.6.5. Spain
- 8.3.6.5.1. Market size and forecast, by Product
- 8.3.6.5.2. Market size and forecast, by Technology Type
- 8.3.6.5.3. Market size and forecast, by Protein Type
- 8.3.6.5.4. Market size and forecast, by End User
- 8.3.6.6. Rest of Europe
- 8.3.6.6.1. Market size and forecast, by Product
- 8.3.6.6.2. Market size and forecast, by Technology Type
- 8.3.6.6.3. Market size and forecast, by Protein Type
- 8.3.6.6.4. Market size and forecast, by End User
- 8.4. Asia-Pacific
- 8.4.1. Key market trends, growth factors and opportunities
- 8.4.2. Market size and forecast, by Product
- 8.4.3. Market size and forecast, by Technology Type
- 8.4.4. Market size and forecast, by Protein Type
- 8.4.5. Market size and forecast, by End User
- 8.4.6. Market size and forecast, by country
- 8.4.6.1. Japan
- 8.4.6.1.1. Market size and forecast, by Product
- 8.4.6.1.2. Market size and forecast, by Technology Type
- 8.4.6.1.3. Market size and forecast, by Protein Type
- 8.4.6.1.4. Market size and forecast, by End User
- 8.4.6.2. China
- 8.4.6.2.1. Market size and forecast, by Product
- 8.4.6.2.2. Market size and forecast, by Technology Type
- 8.4.6.2.3. Market size and forecast, by Protein Type
- 8.4.6.2.4. Market size and forecast, by End User
- 8.4.6.3. India
- 8.4.6.3.1. Market size and forecast, by Product
- 8.4.6.3.2. Market size and forecast, by Technology Type
- 8.4.6.3.3. Market size and forecast, by Protein Type
- 8.4.6.3.4. Market size and forecast, by End User
- 8.4.6.4. Australia
- 8.4.6.4.1. Market size and forecast, by Product
- 8.4.6.4.2. Market size and forecast, by Technology Type
- 8.4.6.4.3. Market size and forecast, by Protein Type
- 8.4.6.4.4. Market size and forecast, by End User
- 8.4.6.5. South Korea
- 8.4.6.5.1. Market size and forecast, by Product
- 8.4.6.5.2. Market size and forecast, by Technology Type
- 8.4.6.5.3. Market size and forecast, by Protein Type
- 8.4.6.5.4. Market size and forecast, by End User
- 8.4.6.6. Rest of Asia-Pacific
- 8.4.6.6.1. Market size and forecast, by Product
- 8.4.6.6.2. Market size and forecast, by Technology Type
- 8.4.6.6.3. Market size and forecast, by Protein Type
- 8.4.6.6.4. Market size and forecast, by End User
- 8.5. LAMEA
- 8.5.1. Key market trends, growth factors and opportunities
- 8.5.2. Market size and forecast, by Product
- 8.5.3. Market size and forecast, by Technology Type
- 8.5.4. Market size and forecast, by Protein Type
- 8.5.5. Market size and forecast, by End User
- 8.5.6. Market size and forecast, by country
- 8.5.6.1. Brazil
- 8.5.6.1.1. Market size and forecast, by Product
- 8.5.6.1.2. Market size and forecast, by Technology Type
- 8.5.6.1.3. Market size and forecast, by Protein Type
- 8.5.6.1.4. Market size and forecast, by End User
- 8.5.6.2. Saudi Arabia
- 8.5.6.2.1. Market size and forecast, by Product
- 8.5.6.2.2. Market size and forecast, by Technology Type
- 8.5.6.2.3. Market size and forecast, by Protein Type
- 8.5.6.2.4. Market size and forecast, by End User
- 8.5.6.3. South Africa
- 8.5.6.3.1. Market size and forecast, by Product
- 8.5.6.3.2. Market size and forecast, by Technology Type
- 8.5.6.3.3. Market size and forecast, by Protein Type
- 8.5.6.3.4. Market size and forecast, by End User
- 8.5.6.4. Rest of LAMEA
- 8.5.6.4.1. Market size and forecast, by Product
- 8.5.6.4.2. Market size and forecast, by Technology Type
- 8.5.6.4.3. Market size and forecast, by Protein Type
- 8.5.6.4.4. Market size and forecast, by End User
CHAPTER 9: COMPETITIVE LANDSCAPE
- 9.1. Introduction
- 9.2. Top winning strategies
- 9.3. Product mapping of top 10 player
- 9.4. Competitive dashboard
- 9.5. Competitive heatmap
- 9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
- 10.1. Agilent Technologies, Inc.
- 10.1.1. Company overview
- 10.1.2. Key executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Business performance
- 10.2. Thermo Fisher Scientific Inc.
- 10.2.1. Company overview
- 10.2.2. Key executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.2.6. Business performance
- 10.2.7. Key strategic moves and developments
- 10.3. Promega Corporation
- 10.3.1. Company overview
- 10.3.2. Key executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.4. New England Biolabs, Inc.
- 10.4.1. Company overview
- 10.4.2. Key executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.5. Danaher Corporation
- 10.5.1. Company overview
- 10.5.2. Key executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
- 10.5.6. Business performance
- 10.5.7. Key strategic moves and developments
- 10.6. Creative Biolabs Limited
- 10.6.1. Company overview
- 10.6.2. Key executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.7. Bio-Rad Laboratories, Inc.
- 10.7.1. Company overview
- 10.7.2. Key executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
- 10.7.6. Business performance
- 10.8. Amgen, Inc.
- 10.8.1. Company overview
- 10.8.2. Key executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
- 10.8.6. Business performance
- 10.8.7. Key strategic moves and developments
- 10.9. Jena Bioscience GmbH
- 10.9.1. Company overview
- 10.9.2. Key executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.10. TAKARA HOLDINGS INC.
- 10.10.1. Company overview
- 10.10.2. Key executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- 10.10.6. Business performance